Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
ACELYRIN, INC. ( (SLRN) ) has provided an announcement.
On January 31, 2025, ACELYRIN, INC., a biopharmaceutical company, terminated its License and Collaboration Agreement with Affibody AB, which was originally established on August 9, 2021. This agreement allowed ACELYRIN exclusive rights to develop, commercialize, and manufacture izokibep for human therapeutic uses globally, except in certain Asian countries. The termination will be effective ninety days after the notice was given, and ACELYRIN will no longer have any material financial or other obligations under this agreement.
More about ACELYRIN, INC.
YTD Price Performance: -40.0%
Average Trading Volume: 1,011,168
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $198.6M
Learn more about SLRN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue